Abstracts tagged "Inflammation"

Abstract Number: 1894 • 2014 ACR/ARHP Annual Meeting
Is It Worth It to Include MRI of the Spine in the ASAS Classification Criteria for Axial Spondyloarthritis?
Manouk de Hooge¹, Jean-Baptiste Pialat², Antoine Feydy³, Monique Reijnierse¹, Pascal Claudepierre⁴, Alain Saraux⁵, Maxime Dougados³ and Désirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Hôpital Edouard Herriot, Lyon, France, ³Descartes University, Cochin Hospital, Paris, France, ⁴Henri Mondor Teaching Hospital, Creteil, France, ⁵CHU de la Cavale Blanche, Brest Cedex, France
Background/Purpose: Spinal MRI lesions suggestive of axial Spondyloarthritis (axSpA) are not included in the ASAS definition of a positive MRI, but do occur in the…
Abstract Number: 660 • 2014 ACR/ARHP Annual Meeting
Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis
María Galindo¹, Elena Gonzalo-Gil², Oscar Toldos³, Carmen García-Herrero², Alicia Usategui¹, Sonia Pérez-Yagüe⁴, Gabriel Criado⁵, Domingo F. Barber⁴ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Servicio de Anatomia Patologica, Hospital 12 de Octubre, Madrid, Spain, ⁴Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose In patients with lupus nephritis (LN), acute renal vascular and atherosclerotic lesions correlate with the degree of inflammation regardless the presence of antiphospholipid antibodies.…
Abstract Number: 2889 • 2014 ACR/ARHP Annual Meeting
The Association Between Changes in Inflammation and High Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis
K P Liao¹, Martin Playford², Michelle A. Frits³, Christine K. Iannaccone⁴, Jonathan S. Coblyn¹, Michael E. Weinblatt⁵, Nancy A. Shadick⁶ and Nehal N. Mehta⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²National Heart, Blood, and Lung Institute, Bethesda, MD, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital/Harvard University, Cambridge, MA, ⁷Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures the functional ability of HDL to remove cholesterol from atherosclerotic plaque. Low HDL efflux capacity is…
Abstract Number: 1823 • 2014 ACR/ARHP Annual Meeting
Inflammation Is Associated with Erosive Progression in Patients with Hand Osteoarthritis: A Prospective Ultrasonography Study
Marion C. Kortekaas^1,2, Wing Yee Kwok³, Monique Reijnierse⁴, Theo Stijnen⁵ and Margreet Kloppenburg⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Flevoziekenhuis, Almere-Stad, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Erosive hand osteoarthritis (OA) is a subset that shows inflammatory features with ultrasound or MRI much more frequent than non-erosive hand OA, and can…
Abstract Number: 611 • 2014 ACR/ARHP Annual Meeting
Autophagy and Unfolded Protein Response: A Fine Balance That Can Influence the Pathogenesis of Ankylosing Spondylitis and Inflammatory Bowel Disease
Nigil Haroon¹, Giuliana Guggino², Zhenbo Zhang¹, Kirby Yee³, Hasan Abdullah⁴, Ricardo Alessandro⁵, Stefania Raimondo⁵, Giovanni Triolo⁵ and Francesco Ciccia², ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Rheumatology Unit, University of Palermo, Palermo, Italy, ³McMaster University, Hamilton, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Palermo, Palermo, Italy
Background/Purpose We have shown an increase in the unfolded protein response (UPR) with decreased ERAP1 or ERAP2 function in an in vitrosystem. Similarly UPR has…
Abstract Number: 2839 • 2014 ACR/ARHP Annual Meeting
BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation
Kichul Ko¹, Denisse Yanez¹, Natalya Kaverina¹, Vladimir M. Liarski¹, Yahui Peng², Li Lan³, Stuart Perper⁴, Annette Schwartz⁵, Liz O'connor⁶, Andrew Souers⁷, Steven Elmore⁷, Lisa Olson⁵, Maryellen L. Giger³, Li Chun Wang⁴ and Marcus R. Clark¹, ¹Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, ²School of Electronic and Information Engineering, Beijing Jiaotong University, Beijing, China, ³Radiology, University of Chicago, Chicago, IL, ⁴Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁶Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁷AbbVie Inc, North Chicago, IL
Background/Purpose Lupus nephritis (LuN) is the most common, severe manifestation of systemic lupus erythematosus (SLE). We have previously shown that glomerulonephritis appears to be a…
Abstract Number: 1815 • 2014 ACR/ARHP Annual Meeting
STAT3-Mediated Regulation of Mitochondrial Membrane Potential Is Critical for NLRP3 Inflammasome Activation
Jehad H. Edwan¹, Raphaela Goldbach-Mansky² and Robert A. Colbert³, ¹NIAMS NIH, Bethesda, MD, ²NIAMS, NIH Building 10 Room 6D47B, Bethesda, MD, ³NIAMS/NIH, Bethesda, MD
Background/Purpose: Self-activating mutations in NLRP3 cause a spectrum of autoinflammatory diseases known as cryopyrin-associated periodic syndromes (CAPS). NLRP3 is a key component of a multiprotein…
Abstract Number: 597 • 2014 ACR/ARHP Annual Meeting
Inflammatory Burden in Recent-Onset Axial Spondyloarthritis
Juan Jose Aznar Sánchez¹, Raul Veroz Gonzalez¹, Adela Gallego Flores¹, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez² and Eugenio Chamizo Carmona¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Mérida, Spain
Background/Purpose Patients with Non-Radiographic Axial Spondylarthritis (non-Rx AxSpA) don't presnt with different clinical manifestations than patients with Ankilosing Spondylitis (AS), although the inflammatory burden measured…
Abstract Number: 2822 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
Edward C. Keystone¹, Peter C. Taylor², Mark C Genovese³, Douglas E. Schlichting⁴, Inmaculada De La Torre⁵, Scott D. Beattie⁴ and Terence Rooney⁴, ¹University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵AVDA. DE LA INDUSTRIA 30, Eli Lilly and Company, Alcobendas, Spain
Background/Purpose: Baricitinib is an oral inhibitor of JAK1/JAK2 being investigated as a treatment for rheumatoid arthritis (RA). In a phase 2b study, baricitinib treatment resulted…
Abstract Number: 1812 • 2014 ACR/ARHP Annual Meeting
Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome
Yin Liu¹, Adriana Almeida de Jesus^2,3, Bernadette Marrero⁴, Dan Yang⁵, Gina A. Montealegre Sanchez⁶, Steve Brooks⁷, Zuoming Deng⁸, Amy Paller⁹, Manfred Boehm⁵ and Raphaela Goldbach-Mansky⁶, ¹Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Translational Autoinflammatory Diseases Section, NIAMS/NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, ⁵Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁶Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD, ⁸Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁹Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: We have recently studied a group of patients with a prominent interferon (IFN) signature in the blood, distinct from IL-1 mediated autoinflammatory diseases. Six…
Abstract Number: 405 • 2014 ACR/ARHP Annual Meeting
14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴, Kelly Young⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Rheumatoid Patient Foundation, Cocoa, FL, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose In RA, irreversible joint damage often begins within the first year of symptom onset. A compelling and growing body of data describing the "uncoupling"…
Abstract Number: 2792 • 2014 ACR/ARHP Annual Meeting
Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a_2A Receptor (A2AR)
Aranzazu Mediero¹, Tuere Wilder² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, ³NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Prior studies demonstrate that adenosine, acting at A2AR, mediates the anti-inflammatory effects of methotrexate (MTX) in models of both acute and chronic inflammation. We…
Abstract Number: 1723 • 2014 ACR/ARHP Annual Meeting
Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies
Michael Johnson¹, Zhenghui Li¹, Michelle Dimon², Tammara A. Wood¹, Robert Lafyatis³, Sarah Arron² and Michael Whitfield⁴, ¹Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dermatology, University of California, San Francisco, San Francisco, CA, ³Arthritis Center, Boston University, Boston, MA, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare and poorly understood systemic autoimmune disease that results in skin fibrosis and severe internal organ involvement. There…
Abstract Number: 344 • 2014 ACR/ARHP Annual Meeting
Reduced Macrophages in the Synovium Contribute to the Effective Treatment of Spontanneous Arthritis Observeded in Human TNF-Transgenic Mice
Robert Birkett¹, Qi Quan Huang¹, Bo Shi² and Richard Pope³, ¹Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ²Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ³Medicine/Rheumatology Div, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose Macrophages in rheumatoid arthritis (RA) synovial tissue (ST) produce high levels of inflammatory cytokines/chemokines and exhibit enhanced differentiation into osteoclasts in the pannus, playing…
Abstract Number: 1861 • 2013 ACR/ARHP Annual Meeting
Neurotrophins Are Involved In Vascular Remodeling Of Giant Cell Arteritis
Kim Heang Ly^1,2, Alexis Régent³, Elsa Molina⁴, Sofiane Saada⁴, Philippe Sindou⁴, Claire Le Jeunne⁵, Antoine Brezin⁶, Veronique witko-Sarsat³, Philippe Bertin⁷, Francois Labrousse⁸, Pierre-Yves Robert⁹, Anne-Laure Fauchais¹⁰, Elisabeth Vidal¹⁰, Luc Mouthon¹¹ and Marie-Odile Jauberteau⁴, ¹CHU Dupuytren, Limoges, Limoges, France, ²Immunology Laboratory, EA3842, Limoges Medical school, Limoges, France, ³Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, ⁴Immunology Laboratory, EA 3842, Limoges Medical School, Limoges, France, ⁵Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ⁶Service d’ophtalmologie, hôpital Cochin, AP-HP, Paris, France, ⁷Hôpital Dupuytren, Limoges, France, ⁸Department of Pathology, Limoges University Hospital, Limoges, France, ⁹Departement of Ophthalmology, Limoges University Hospital, Limoges, France, ¹⁰Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessels vasculitis. Hhistopathological findings show cellular infiltrates, internal elastic lumina disruption and intimal hyperplasia leading to luminal stenosis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].